Quoin Pharmaceuticals Ltd (QNRX)
4.57
0.00 (0.00%)
Upcoming Events
Latest Headlines
Form 8-K Quoin Pharmaceuticals, For: Jun 04
June 4, 2026 4:04 PM - SEC Filing
Japan's health ministry grants orphan drug status to Quoin's QRX003
June 4, 2026 8:31 AM - StreetInsider
Quoin Pharmaceuticals Announces Japan's MHLW Grants Orphan Drug Designation for QRX003 in Netherton Syndrome
June 4, 2026 8:30 AM - Globe NewsWire
Form SCHEDULE 13G Quoin Pharmaceuticals, Filed by: INTEGRATED CORE STRATEGIES (US) LLC
June 2, 2026 5:14 PM - SEC Filing
Quoin Pharmaceuticals submits IND for rare skin disorder treatment
June 2, 2026 8:31 AM - StreetInsider
Quoin Pharmaceuticals Submits IND Application for QRX003 in Peeling Skin Syndrome
June 2, 2026 8:30 AM - Globe NewsWire
Form 424B3 Quoin Pharmaceuticals,
June 2, 2026 6:09 AM - SEC Filing
Form SCHEDULE 13G/A Quoin Pharmaceuticals, Filed by: ADAR1 Capital Management, LLC
May 15, 2026 8:16 PM - SEC Filing
Form SCHEDULE 13G/A Quoin Pharmaceuticals, Filed by: Stonepine Capital Management, LLC
May 15, 2026 5:27 PM - SEC Filing
Form SCHEDULE 13G/A Quoin Pharmaceuticals, Filed by: Woodline Partners LP
May 15, 2026 9:13 AM - SEC Filing
Form 8-K Quoin Pharmaceuticals, For: May 07
May 7, 2026 4:15 PM - SEC Filing
Form 10-Q Quoin Pharmaceuticals, For: Mar 31
May 7, 2026 1:35 PM - SEC Filing
Quoin Pharmaceuticals Provides Corporate Update and Reports First Quarter 2026 Financial Results
May 7, 2026 8:30 AM - Globe NewsWire
Lucid Capital Markets Starts Quoin Pharmaceuticals (QNRX) at Buy
May 4, 2026 6:08 AM - StreetInsider
Quoin Pharmaceuticals to Announce Corporate Update and First Quarter 2026 Financial Results on Thursday, May 7, 2026
April 30, 2026 8:30 AM - Globe NewsWire
Form SCHEDULE 13G/A Quoin Pharmaceuticals, Filed by: Aberdeen Group plc
April 29, 2026 6:41 AM - SEC Filing
CORRECTION -- Quoin Pharmaceuticals Provides Clinical and Regulatory Update for QRX009 Topical Rapamycin Development Programs
April 28, 2026 12:02 PM - Globe NewsWire
Quoin Pharmaceuticals plans investigator-led studies for QRX009
April 28, 2026 8:32 AM - StreetInsider
Quoin Pharmaceuticals Provides Clinical and Regulatory Update for QRX009 Topical Rapamycin Development Programs
April 28, 2026 8:30 AM - Globe NewsWire
Form 4 Quoin Pharmaceuticals, For: Mar 26 Filed by: Stonepine Capital Management, LLC
March 31, 2026 1:59 PM - SEC Filing
Form 10-K Quoin Pharmaceuticals, For: Dec 31
March 26, 2026 4:39 PM - SEC Filing
Form 8-K Quoin Pharmaceuticals, For: Mar 26
March 26, 2026 9:36 AM - SEC Filing
Quoin Pharmaceuticals Provides Corporate Update and Reports Fourth Quarter and Full-Year 2025 Financial Results
March 26, 2026 8:30 AM - Globe NewsWire
Quoin gets FDA feedback that single study may support QRX003 approval
March 25, 2026 8:31 AM - StreetInsider
Quoin Pharmaceuticals Provides Clinical and Regulatory Update from Constructive Type C Meeting with U.S. FDA for QRX003 in Netherton Syndrome
March 25, 2026 8:31 AM - Globe NewsWire
Quoin Pharmaceuticals to Announce Corporate Update and Fourth Quarter and Full-Year 2025 Financial Results on Thursday, March 26, 2026
March 19, 2026 8:30 AM - Globe NewsWire
Form 8-K Quoin Pharmaceuticals, For: Mar 11
March 11, 2026 4:32 PM - SEC Filing
Quoin Pharmaceuticals receives FDA fast track designation for QRX003
March 11, 2026 8:30 AM - StreetInsider
Quoin Pharmaceuticals Announces FDA Grants Fast Track Designation for QRX003 for the Treatment of Netherton Syndrome
March 11, 2026 8:30 AM - Globe NewsWire
Full Article List
